Glycomine Inc. Details

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substr...
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine's lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
Employees
HQ
+1 650-401-2016
Location
San Carlos, California
Revenue
$8.7M

Notable Alumni

Giacomo Chiesi
Head of Global Rare Diseases
Chiesi Group
Qiuhong Yang
Senior Scientist II, Pharmaceutical Operations & Supply Chain
Exelixis
Deirdre Foley
Senior Program Manager
Ambys Medicines
Christopher Starr
Cofounder and Executive Chairman
Monopar Therapeutics Inc.

Employees

VP of Pharmaceutical Development and CMC
Board Member
Senior Director of Clinical Operations
Chief Scientific Officer
VP, Preclinical Development

Prospect on LinkedIn

Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download ExtensionRepresents linkedin prospector
Browse Apollo's Directories

"We love the interface, the experience, and most importantly… the results."

Erik Straub

Chief Marketing Officer, Kickfurther

"Using Apollo, we’ve solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects."

Michael Transon

CEO, Victorious

Ready to try it out?

Get started for free, then add your whole team. You can always talk to sales if you’re interested in advanced plans.